Cuscal (CCL) – Paymark Acquisition + Raise: What’s Actually Going On

Cuscal has finally pulled the trigger on something meaningful: they’re buying Paymark in NZ for $27m and raising $30m to do it. On the surface it looks like a pretty straightforward bolt‑on, but once you dig through the docs there’s a bit more going on here.

First thing: Paymark isn’t some random fintech. It’s basically the backbone of NZ’s payments switching infrastructure — 1.5B+ transactions a year, long‑standing relationships with all the major banks, and a product set that looks almost identical to Cuscal’s Australian acquiring/switching business. It’s the closest thing to a “like‑for‑like” expansion you’ll see in this sector.

The raise is clean enough. Placement at $4.00, 5% discount, fully underwritten. SPP up to $3m, same price or 1.5% below 5‑day VWAP. No bells and whistles. No options. No weird structures. Just straight equity to fund the deal and keep CET1 in the 18–19% range. They’re not stretching the balance sheet.

The interesting bit is the put option. Worldline has to run through a French Works Council process before they can formally sell the asset. That can take up to two months. Cuscal has exclusivity, but Worldline still has to actually exercise the put. If they don’t, they reimburse Cuscal’s transaction costs. So the deal isn’t 100% locked, but it’s close enough that Cuscal is raising the money now.

Financially, the numbers are surprisingly decent. They’re paying ~5x FY27E NPAT. Mid‑single‑digit EPS accretion in FY27, mid‑teens ROIC, and >25% ROIC once Paymark finishes its switch upgrade program. That upgrade is a $21m multi‑year spend (FY26–FY30), but it’s funded out of Paymark’s own cashflow — Cuscal doesn’t have to tip in more capital. That’s important.

Integration risk is low. Paymark already runs as a standalone business under Worldline. Minimal reliance on group systems. Local management stays. Cuscal basically plugs it into the group and leaves it alone while they keep working on Indue and the risk uplift program. This isn’t a distraction play.

Strategically, it makes sense. NZ is a familiar market, similar regulatory environment, similar client base, and a concentrated switching landscape. Cuscal gets immediate scale and a second geography without having to build anything from scratch. It’s not a moonshot — it’s a steady, infrastructure‑led expansion.

The only real question mark is execution timing. The French Works Council process is the gating item. If that drags, completion drags. But the raise is done, the docs are signed, and both sides look aligned.

So the short version:

Cuscal is buying a real asset, at a reasonable multiple, with limited integration risk, funded cleanly, and with earnings accretion baked in.

Not a bad move in a sector where most “growth” stories are smoke and mirrors.

DISC: Hold IRL & SM also participating in the SPP

Cuscal (CCL) — 1H26 Result & Forward Value

I participated in the IPO and have followed CCL closely since listing. The 1H26 result confirms what I backed at float: this is a defensive, transaction‑driven operator with genuine operating leverage now starting to show through.

The core of the story:

CCL is one of only five entities in Australia with full payments‑rail connectivity (the four majors + Cuscal). That regulatory moat is real, expensive to replicate, and getting stronger as compliance, cyber, and fraud‑monitoring costs rise across the sector. Their B2B model means they don’t compete with their own customers, and the client base is long‑tenured, contracted, and volume‑linked.

1H26 showed three things clearly:

• Underlying NPAT +13% — the business is scaling again after the heavy FY22–FY25 investment cycle.

• Transaction volumes +9% — broad‑based strength across issuing, acquiring, and payments.

• Indue acquisition is already accretive — $5.3m NOI contribution in one month, with $15–20m post‑tax synergies reaffirmed.

Why it matters:

This is a classic “earnings compounder hiding inside a regulated utility.” Once Indue is fully integrated (FY29), the combined entity should be structurally more profitable, more diversified, and more resilient. The synergy targets are large relative to the current earnings base, and management has a track record of disciplined execution.

Forward value:

If CCL delivers mid‑teens underlying NPAT growth (as guided), maintains its capital strength, and realises even the midpoint of Indue synergies, the earnings profile in FY28–FY30 looks meaningfully higher than today. The market is still pricing CCL like a slow‑moving payments processor; the trajectory now looks more like a scaled infrastructure provider with operating leverage ahead of it.

Disclosure: I’m holding for that multi‑year rerate.

I seek the code where margins gleam,

To clip the ticket is my dream.

But giants stalk the minnow's field,

Their market power might make us yield.

I'm not holding this one, but came across this today:

https://arichlife.com.au/potential-hidden-small-cap-gem-still-flying-under-the-radar/ [10-April-2025]

by Claude Walker @ A Rich Life. Now no longer behind a paywall.

Not my type of company personally, I tend to shy away from fintechs and biotechs, and this seems to be a fintech, even if it's not really any new tech, just old tech done well by the looks of it. More a backroom payments system company. But a trusted one (not like ISX, a.k.a. Southern Cross Payments).